128 related articles for article (PubMed ID: 38534886)
1. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
[TBL] [Abstract][Full Text] [Related]
2. Factor XI inhibition in patients with acute coronary syndrome.
Raffo C; Capodanno D
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i29-i34. PubMed ID: 38867863
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance.
Ferri N; Colombo E; Corsini A
Hematol Rep; 2024 Mar; 16(1):151-163. PubMed ID: 38534886
[TBL] [Abstract][Full Text] [Related]
4. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
[TBL] [Abstract][Full Text] [Related]
5. News at XI: moving beyond factor Xa inhibitors.
Fredenburgh JC; Weitz JI
J Thromb Haemost; 2023 Jul; 21(7):1692-1702. PubMed ID: 37116752
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions.
Gómez-Outes A; Suárez-Gea ML; Pérez-Cabeza AI; García-Pinilla JM
Expert Opin Pharmacother; 2022 Dec; 23(17):1941-1955. PubMed ID: 36398362
[TBL] [Abstract][Full Text] [Related]
7. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.
Ferri N; Colombo E; Tenconi M; Baldessin L; Corsini A
Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745692
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical appraisal of factor XI inhibitor drugs.
Occhipinti G; Laudani C; Spagnolo M; Finocchiaro S; Mazzone PM; Faro DC; Mauro MS; Rochira C; Agnello F; Giacoppo D; Ammirabile N; Landolina D; Imbesi A; Sangiorgio G; Greco A; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):245-258. PubMed ID: 38196141
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies.
Kanefendt F; Brase C; Jungmann N; Fricke R; Engelen A; Schmitz S
Br J Clin Pharmacol; 2024 Apr; 90(4):1036-1049. PubMed ID: 38048692
[TBL] [Abstract][Full Text] [Related]
11. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.
Roehrig S; Ackerstaff J; Jiménez Núñez E; Teller H; Ellerbrock P; Meier K; Heitmeier S; Tersteegen A; Stampfuss J; Lang D; Schlemmer KH; Schaefer M; Gericke KM; Kinzel T; Meibom D; Schmidt M; Gerdes C; Follmann M; Hillisch A
J Med Chem; 2023 Sep; 66(17):12203-12224. PubMed ID: 37669040
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
Chan NC; Weitz JI
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans.
Piel I; Engelen A; Lang D; Schulz SI; Gerisch M; Brase C; Janssen W; Fiebig L; Heitmeier S; Kanefendt F
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):411-425. PubMed ID: 37365440
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
